Impax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a document filed in a Alabama federal court this week.
The Alabama-based pharmacy filed the proposed class action suit against Impax in January, alleging that the pharmaceutical company was sending unsolicited faxes advertising its EpiPen alternative without any option to opt out and occupying the use of their fax machines.
Get the full story at our sister site, Drug Delivery Business News.
The post Impax settles ‘fax-blasting’ class action suit over EpiPen alternative appeared first on MassDevice.